Polychemotherapeutic treatment of patients with metastatic breast cancer.
A total of 79 metastatic breast cancer patients were treated with a combination of vincristine, doxorubicin and cyclophosphamide (VDC). In 59% of the patients remission occurred, in 23% the condition did not change, while in 18% progression of the disease was observed. The mean duration of the remission was 11 months. The side-effects did practically not influence the course of the treatment.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide